19 Dec Year in Review 2025
RiverVest Year in Review: 2025...
09 Dec Portfolio Company Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals
DECEMBER 2025Portfolio Company Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals ST. LOUIS--(December 8, 2025)-- Bluejay Therapeutics – a RiverVest Venture Fund V portfolio company – has entered into a definitive agreement to be acquired by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a former RiverVest portfolio company focusing...
14 Oct With $115 Million in Hand, Biotech Startup Eyes the Finish Line
Nicklaus: With $115 Million in Hand, Biotech Startup Eyes the Finish Line...
24 Sep Could Excess Cortisol Be Driving Type 2 Diabetes Resistance?
/ EXPERT INSIGHTSCould Excess Cortisol Be Driving Type 2 Diabetes Resistance? by Niall O'Donnell, PhDManaging Director of RiverVestVenture PartnersWhy taming a stress hormone might be the next breakthrough in type 2 diabetes care(September 24, 2025) - Millions of people on type 2 diabetes (T2B) regimens do...
19 Aug NEWS / RiverVest Mourns Passing of Ronald T. Borchardt, PhD
August 2025RiverVest Mourns Passing of Ronald T. Borchardt, PhD,RiverVest Scientific Advisory Board Member Ronald T. Borchardt, PhDFebruary 18, 1944 - July 15, 2025In MemoriamWith great sadness, RiverVest mourns the passing of Dr. Ronald T. Borchardt, a valued member of our scientific advisory board since 2015. Ron’s...
15 May The Sugar Fix: A New Approach to Treating a Rare Glycosylation Disorder
Glycosylation is crucial to the development of healthy organs and tissues. Could replacing a missing sugar help patients with a rare glycosylation disorder improve coordination and mobility? ...
28 Feb RIVERVEST NEWS: June Newsletter
RIVERVEST NEWSLETTERJune 2025 Issue RiverVest invites you to read our latest newsletter, featuring:2025 Annual Meeting RecapRiverVest Portfolio: Year in ReviewThe Sugar Fix: A New Approach to Treating a Rare Glycosylation DisorderPortfolio NewsRiverVest News features insights and updates on...
12 Feb Portfolio Company Spotlight: Alleviant Medical (Chronic Heart Failure)
Learn how Alleviant's no-implant approach addresses the full spectrum of chronic heart failure....
19 Dec Year in Review 2024
RiverVest Year in Review: 2024...
12 Dec RiverVest Welcomes John Cambier and Gary DeCrescenzo to Scientific Advisory Board
ST. LOUIS (December 12, 2024)—RiverVest Venture Partners, a leading life science venture capital firm, today announced that John C. Cambier, Ph.D., and Gary De Crescenzo have joined the firm’s Scientific Advisory Board. Composed of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance...
14 Nov Diabetes Treatment: A Story of Complicated Progress and Great Potential
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
16 Oct RiverVest Venture Partners Welcomes Nafise Masoumi as Senior Associate
OCTOBER 2024RiverVest Venture Partners Welcomes Nafise Masoumi as Senior Associate Nafise Masoumi, PhDST. LOUIS--(October 16, 2024)--Life sciences venture capital firm RiverVest Venture Partners today announced that Nafise Masoumi, Ph.D. has joined the firm as senior associate based in the San Diego office, where she will focus...
05 Sep Meet the Leader: Lyn Baranowski, CEO of Avalyn Pharma
RiverVest speaks with Lyn Baranowski, CEO of portfolio company Avalyn Pharma, about who she is, what brought her to Avalyn, and what fuels her passion for building great companies....
18 Jul RiverVest Venture Partners Promotes Andrew Kleiboeker and Jeff Seitz
JULY 2024RiverVest Venture Partners Announces Promotions ST. LOUIS (July 18, 2024)ST. LOUIS, July 18, 2024– RiverVest Venture Partners today announced the promotions of two members of its team. Andrew Kleiboeker has been promoted to associate, and Jeff Seitz to senior analyst. "Both Andrew and Jeff have shown...
10 Jun Niall O’Donnell, Ph.D. Honored by UC San Diego’s Rady School of Management’s Sullivan Center for Entrepreneurship
June 2024O'Donnell Honored for Entrepreneurial Achievement by UC San Diego's Rady School of Management Niall O'Donnell, Ph.D. RiverVest Managing Director San Diego, CA (June 5, 2024) – UC San Diego’s Rady School of Management named Niall O’Donnell, Ph.D. (Rady MBA Class of 2006) the Sullivan Center for...
26 Feb Global Clinical Trial Investigates Novel Heart Failure Treatment
RiverVest's latest Expert Insight explores the role of patient advocacy groups in therapeutic drug development for patients with rare diseases such as mitochondrial disease. ...
- 1
- 2